Friday, October 31, 2014
The Department of Defense (DoD), through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. Profectus BioSciences is a Baltimore, Md.-based clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases.
Cytomedix, a Gaithersburg, Md.-based pioneer in biodynamic therapies, has launched its new corporate brand identity, Nuo Therapeutics. The company intends to change its corporate name to Nuo Therapeutics, following shareholder approval of the name change proposal at its Annual General Meeting of the company’s shareholders on Nov. 12.
ReproCELL, a venture company in the iPS cell business originating from the University of Tokyo and Kyoto University, has acquired U.K.-based Reinnervate, a spin-out company from Durham University, a center of excellence in cell biology research, and BioServe Biotechnologies, based in Maryland, to accelerate its iPS cell business.
CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium’s most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution, which employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.